

The Plasminogen Fibrinolytic Pathway Is Required for Hematopoietic Regeneration

Beate Heissig, Leif R. Lund, Haruyo Akiyama, Makiko Ohki, Yohei Morita, John Rømer, Hiromitsu Nakauchi, Ko Okumura, Hideoki Ogawa, Zena Werb, Keld Danø, and Koichi Hattori*

*Correspondence: hattoriko@yahoo.com

DOI 10.1016/j.stem.2008.06.010

(Cell Stem Cell 7, 658–670; December 2007)

The authors wish to correct an inaccurate statement made in the Experimental Procedures on the concentration of the drug tPA (p. 668).

The following sentence appeared in the published article:

Mice were injected with human recombinant tPA (kindly provided by Eisai, Tokyo, Japan) intraperitoneally at a concentration of 1.25×10^6 IU = 1 mg/kg body weight daily or PBS for a total of 3 days. (Recommended tPA dosage in humans for clinical use is 10 mg/kg.)

The corrected passage is printed below:

Mice were injected with human recombinant tPA (kindly provided by Eisai, Tokyo, Japan) intraperitoneally at a concentration of 1.25×10^6 IU = 10 mg/kg body weight daily or PBS for a total of 3 days. (Recommended tPA dosage in humans for clinical use is 10 mg/kg.)

The authors deeply regret the error.